I could see a total B platform partnership coming. The PR yesterday included all the indications of B in it for a reason I believe. They mentioned recent partnering interactions and stated that B for ABSSSI, B-OM, and all of the B digestive platform (my words) are being looked as interest for defensin-based therapies intensifies. We already have partnered the lowest grossing part of our B platform. Anything beyond this is a win. IMO